Home/ Stocks/ APGE

Apogee Therapeutics, Inc. Common Stock

APGE XNAS

$134.49 +0.26 (+0.19%) ▲ 15-min delayed

Open

$134.33

High

$134.58

Low

$134.25

Volume

1.23M

Market Cap

$10.15B

About Apogee Therapeutics, Inc. Common Stock

Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 261 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$0	$-74,111,000	$-1.06
FY 2025	$0	$-255,843,000	$-4.22
Q3 2025	$0	$-65,021,000	$-1.11
Q2 2025	$0	$-66,096,000	$-1.13

TickerDaily Coverage

Why Is Apogee Therapeutics, Inc. Common Stock (APGE) Stock Up 46.8% Today?

Market News Alex Chen · Jun 22, 2026

Apogee Therapeutics stock exploded 46.8% on Monday, June 22, 2026, reaching $132.66 as trading...

View All Coverage →

Get APGE Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Apogee Therapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.